Chemoprevention of Colorectal Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31563626.
- Also identified by DOI 10.1053/j.gastro.2019.06.047 and PMC identifier 6981249.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although colorectal cancer (CRC) screening has reduced the incidence of and mortality from CRC, chemoprevention strategies have the potential to further reduce CRC incidence and mortality. Chemoprevention agents might be used for average-risk as well as high-risk groups, and to prevent CRC recurrence after therapy. CRC chemoprevention agents that have been studied include aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, statins, agents that target metabolic pathways, and vitamins and minerals. We review the prospect of chemoprevention of CRC, results from preclinical and human studies, challenges, and future directions.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Anticarcinogenic Agents
- Colorectal Neoplasms
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Vitamins